ArticleSeminars in arthritis and rheumatism2021
Incidence, survival, and diagnostic trends in GCA across seven decades in a North American population-based cohort.
Article in Seminars in arthritis and rheumatism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 21 citations in OpenAlex.
- Glucagon-Like Peptide 1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Clinical Profile of Giant Cell Arteritis and Polymyalgia Rheumatica in a Tertiary Care Hospital in South India.Cureus · 2026Article
- Population-Based Performance of Inflammatory Markers in Giant Cell Arteritis.American journal of ophthalmology · 2025Article
- Prevalence and Clinical Characteristics of Vasculitis in the Alaska Native and American Indian Peoples of Alaska.Arthritis care & research · 2025Article
- Predictors of Permanent Vision Loss in Giant Cell Arteritis.Neuro-ophthalmology (Aeolus Press) · 2025Article
- The Set up and the Triggers: An Update on the Risk Factors for Giant Cell Arteritis.Current neurology and neuroscience reports · 2024Review
- Association between sinusitis and incident rheumatic diseases: a population-based study.RMD open · 2024Article
- Reappraisal of large artery involvement in giant cell arteritis: a population-based cohort over 70 years.RMD open · 2024Article
- Persistent aortic inflammation in patients with giant cell arteritis.Autoimmunity reviews · 2023Review
- Burden, Causes, and Outcomes of Hospitalization in Patients With Giant Cell Arteritis: A US National Cohort Study.Arthritis care & research · 2023Article
- Lower Frequency of Comorbidities Prior to Onset of Giant Cell Arteritis: A Population-Based Study.The Journal of rheumatology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
objectivesTo analyze trends in the incidence and use of diagnostic modalities for GCA in a population-based cohort over the past seven decades. To explore survival trends in patients with GCA compared with the general population.
methodsA population-based cohort of patients diagnosed with GCA was extended with new incident cases from 2010 to 2019. Three time periods were compared: Period One (1950-1979), Period Two (1980-1999), and Period Three (2000-2019). Cases were classified as: Diagnostic Group One, temporal artery biopsy (TAB) positive; Diagnostic Group Two, TAB-negative or not done with positive large-vessel imaging; or Diagnostic Group Three, clinical diagnosis of GCA. Survival was evaluated by comparing Kaplan-Meier estimated mortality rates for cases of GCA against expected mortality rates from Minnesota life tables
resultsAge- and sex-adjusted incident rates per 100,000 ≥ 50 years of age (95% CI) were 13.5 (10.1, 16.9) in Period One, 21.0 (17.1, 25.0) in Period Two, and 15.0 (12.4, 17.5) in Period Three. The percent of patients in Diagnostic Group One decreased over the three time periods (89%, 86%, and 72%) while the patients in Diagnostic Group Three increased (11%, 14%, and 17%). Standardized mortality ratios (95% CI) were 1.03 (0.79, 1.32), 1.11 (0.91, 1.34), and 0.82 (0.64, 1.04) across Periods 1-3, respectively.
conclusionsIncidence of GCA in females in the population declined, resulting in a decreasing overall incidence. More patients have been identified by large-vessel imaging and fewer by positive TABs. No significant difference in survival between patients with GCA and the general population was observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.